Search

Coloplast A-S (Class B)

Suletud

606 0.56

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

600

Max

606.6

Põhinäitajad

By Trading Economics

Sissetulek

-107M

805M

Müük

28M

7B

P/E

Sektori keskmine

33.124

77.256

Aktsiakasum

4.67

Dividenditootlus

3.78

Kasumimarginaal

11.569

Töötajad

16,814

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+11.86% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.78%

2.33%

Turustatistika

By TradingEconomics

Turukapital

-881M

136B

Eelmine avamishind

605.44

Eelmine sulgemishind

606

Coloplast A-S (Class B) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. nov 2025, 23:59 UTC

Tulu

Singtel's 1st Half Net Profit Surges

11. nov 2025, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11. nov 2025, 22:21 UTC

Tulu

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11. nov 2025, 23:52 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11. nov 2025, 23:44 UTC

Tulu

Singtel's 1H Net Profit Surges

11. nov 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11. nov 2025, 23:18 UTC

Tulu

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11. nov 2025, 23:15 UTC

Tulu

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11. nov 2025, 23:14 UTC

Tulu

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11. nov 2025, 23:12 UTC

Tulu

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11. nov 2025, 23:11 UTC

Tulu

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11. nov 2025, 23:10 UTC

Tulu

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11. nov 2025, 23:04 UTC

Market Talk

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11. nov 2025, 21:50 UTC

Market Talk
Tulu

Health Care Roundup: Market Talk

11. nov 2025, 21:46 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11. nov 2025, 21:41 UTC

Tulu

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11. nov 2025, 21:40 UTC

Tulu

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11. nov 2025, 21:39 UTC

Tulu

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11. nov 2025, 21:39 UTC

Tulu

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11. nov 2025, 21:39 UTC

Tulu

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11. nov 2025, 21:38 UTC

Tulu

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11. nov 2025, 21:38 UTC

Tulu

Aristocrat: Final Dividend 49 Australian Cents/Share

11. nov 2025, 21:37 UTC

Tulu

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11. nov 2025, 21:36 UTC

Tulu

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11. nov 2025, 21:35 UTC

Tulu

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11. nov 2025, 21:35 UTC

Tulu

Alcon 3Q Adj EPS 79c >ALC

11. nov 2025, 21:35 UTC

Tulu

Alcon 3Q Rev $2.61B >ALC.EB

11. nov 2025, 21:35 UTC

Tulu

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11. nov 2025, 21:35 UTC

Tulu

Alcon 3Q EPS 48c >ALC.EB

Coloplast A-S (Class B) Prognoos

Hinnasiht

By TipRanks

11.86% tõus

12 kuu keskmine prognoos

Keskmine 901.38 DKK  11.86%

Kõrge 1,056 DKK

Madal 720 DKK

Põhineb 8 Wall Streeti analüütiku instrumendi Coloplast A-S (Class B) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

2

Osta

4

Hoia

2

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat